Literature DB >> 33680575

DisCoVering potential candidates of RNAi-based therapy for COVID-19 using computational methods.

Narjes Rohani1,2, Fatemeh Ahmadi Moughari1, Changiz Eslahchi1,2.   

Abstract

The ongoing pandemic of a novel coronavirus (SARS-CoV-2) leads to international concern; thus, emergency interventions need to be taken. Due to the time-consuming experimental methods for proposing useful treatments, computational approaches facilitate investigating thousands of alternatives simultaneously and narrow down the cases for experimental validation. Herein, we conducted four independent analyses for RNA interference (RNAi)-based therapy with computational and bioinformatic methods. The aim is to target the evolutionarily conserved regions in the SARS-CoV-2 genome in order to down-regulate or silence its RNA. miRNAs are denoted to play an important role in the resistance of some species to viral infections. A comprehensive analysis of the miRNAs available in the body of humans, as well as the miRNAs in bats and many other species, were done to find efficient candidates with low side effects in the human body. Moreover, the evolutionarily conserved regions in the SARS-CoV-2 genome were considered for designing novel significant siRNA that are target-specific. A small set of miRNAs and five siRNAs were suggested as the possible efficient candidates with a high affinity to the SARS-CoV-2 genome and low side effects. The suggested candidates are promising therapeutics for the experimental evaluations and may speed up the procedure of treatment design. Materials and implementations are available at: https://github.com/nrohani/SARS-CoV-2.
© 2021 Rohani et al.

Entities:  

Keywords:  COVID-19; RNA intervention-based therapy; SARS-CoV-2; Virology; miRNA; miRNA-mRNA interaction; siRNA design

Year:  2021        PMID: 33680575      PMCID: PMC7919535          DOI: 10.7717/peerj.10505

Source DB:  PubMed          Journal:  PeerJ        ISSN: 2167-8359            Impact factor:   2.984


  6 in total

1.  Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spread.

Authors:  Shubhankar Ambike; Cho-Chin Cheng; Martin Feuerherd; Stoyan Velkov; Domizia Baldassi; Suliman Qadir Afridi; Diana Porras-Gonzalez; Xin Wei; Philipp Hagen; Nikolaus Kneidinger; Mircea Gabriel Stoleriu; Vincent Grass; Gerald Burgstaller; Andreas Pichlmair; Olivia M Merkel; Chunkyu Ko; Thomas Michler
Journal:  Nucleic Acids Res       Date:  2022-01-11       Impact factor: 16.971

2.  Effect of insilico predicted and designed potential siRNAs on inhibition of SARS-CoV-2 in HEK-293 cells.

Authors:  Sayed Sartaj Sohrab; Sherif Aly El-Kafrawy; Esam Ibraheem Azhar
Journal:  J King Saud Univ Sci       Date:  2022-03-16

Review 3.  microRNAs and Inflammatory Immune Response in SARS-CoV-2 Infection: A Narrative Review.

Authors:  Beatrice Maranini; Giovanni Ciancio; Manuela Ferracin; Rosario Cultrera; Massimo Negrini; Silvia Sabbioni; Marcello Govoni
Journal:  Life (Basel)       Date:  2022-02-15

4.  In silico prediction and experimental evaluation of potential siRNAs against SARS-CoV-2 inhibition in Vero E6 cells.

Authors:  Sayed Sartaj Sohrab; Sherif Aly El-Kafrawy; Esam Ibraheem Azhar
Journal:  J King Saud Univ Sci       Date:  2022-04-26

Review 5.  Development and application of ribonucleic acid therapy strategies against COVID-19.

Authors:  Lin Ning; Mujiexin Liu; Yushu Gou; Yue Yang; Bifang He; Jian Huang
Journal:  Int J Biol Sci       Date:  2022-08-01       Impact factor: 10.750

Review 6.  Noncoding RNA therapeutics - challenges and potential solutions.

Authors:  Melanie Winkle; Sherien M El-Daly; Muller Fabbri; George A Calin
Journal:  Nat Rev Drug Discov       Date:  2021-06-18       Impact factor: 84.694

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.